Clinical trialPhase 2Recruiting
Utility of ctDNA in Early Switch of First-line Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma
A Phase 2 Study Assessing Utility of ctDNA in Early Switch of First-line Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma
- Outcome
- Ongoing
- Phase
- Phase 2
- Status
- Recruiting
- Study type
- Interventional
- Start
- 9 September 2025
- Expected end
- 30 September 2030
- Enrollment
- 50 participants
- Sites
- 1
- Primary outcomes
- Part 1:Change in ctDNA fold-change at Week 4; Part 1: Number of Radiographic Response Status Responders vs. Number of Non-Responders; Part 2: Progression-Free Survival (PFS)
- Sponsor
- Other
- Results posted
- No
- Last update
- 21 September 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is to understand whether a blood-based test called circulating tumor DNA (ctDNA) can detect whether participants are having a desired tumor shrinkage or an undesired lack of tumor shrinkage, and to study whether these levels of ctDNA can be used to make treatment decisions faster than the current standard approach, which is to wait 8 weeks after starting chemotherapy to obtain participant first imaging scans since starting chemotherapy.